RISK Factors
|
Total Patients N = 100
|
P value
|
Odds Ratio
|
Confidence Interval
|
---|
No of patients
|
Patients with CPE (n = 26) (%)
|
Patients without CPE (n = 74) (%)
|
---|
Sex (Male)
|
58
|
17 (65.3)
|
41 (55.4)
|
0.37
|
1.52
|
0.600
|
3.849
|
Antibiotics use
|
Carbapenems
|
14
|
7 (26.9)
|
7 (9.5)
|
0.027
|
3.528
|
1.1
|
11.304
|
Cephalosporins
|
45
|
13 (50)
|
32 (43.2)
|
0.55
|
1.313
|
0.536
|
3.125
|
Aminoglycosides
|
11
|
6 (23.1)
|
5 (6.8)
|
0.032
|
4.14
|
1.143
|
14.994
|
Augmentin
|
5
|
1 (3.8)
|
4 (5.4)
|
0.75
|
0.700
|
0.075
|
6.565
|
Fluoroqinolones
|
9
|
3 (11.5)
|
6 (8.1)
|
0.59
|
1.478
|
0.342
|
6.393
|
Interventions used
|
Central venous line
|
35
|
12 (46.2)
|
23 (31.1)
|
0.16
|
1.901
|
0.761
|
4.744
|
Ventilator
|
61
|
21 (80.8)
|
40 (54.1)
|
0.01
|
3.570
|
1.216
|
10.483
|
Peripheral catheter
|
83
|
22 (84.6)
|
61 (82.4)
|
0.79
|
1.172
|
0.345
|
3.978
|
Naso-gastric tube
|
43
|
15 (57.7)
|
28 (37.8)
|
0.07
|
2.240
|
0.903
|
5.559
|
Oxygen Mask
|
21
|
6 (23.1)
|
15 (20.3)
|
0.7
|
1.180
|
0.403
|
3.454
|
Co-morbid conditions
|
Surgery
|
15
|
7 (26.9)
|
8 (10.8)
|
0.048
|
3.039
|
0.976
|
9.461
|
Chronic lung disease
|
20
|
2 (7.7)
|
18 (24.3)
|
0.06
|
0.259
|
0.056
|
1.206
|
Neoplasia
|
7
|
1 (3.8)
|
6 (8.1)
|
0.4
|
0.453
|
0.052
|
3.955
|
Multivariate analysis
|
Ventilator
| |
0.027
|
0.291
|
0.097
|
0.871
|
Aminoglycosides
| |
0.046
|
0.257
|
0.068
|
0.975
|
-
CPE carbapenemase producing Enterobacteriaceae